Lineage Cell Therapeutics receives grant to fund novel bio-retinal patch

Source/Disclosures

Published by:

Source:

Press Release

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

ADDED TO EMAIL ALERTS

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Lineage Cell Therapeutics was awarded a grant worth more than $500,000 for the development of a bio-retinal patch for the treatment of retinal diseases, according to a press release.

The grant was awarded by the Israel Innovation Authority and is worth up to 1.95 million Israeli new shekels, or roughly $573,000. The patch is being developed by Cell Cure Neurosciences, a subsidiary of Lineage Cell Therapeutics, in partnership with Precise Bio.

“The clinical data we are generating from our OpRegen program is increasing our confidence in the use of cell transplants to treat serious retinal conditions such as dry AMD,” Brian M. Culley, CEO of Lineage Cell Therapeutics, said in the release. “OpRegen is a suspension of RPE cells, but in certain patients with dry AMD or other degenerative conditions, there may be a role for a scaffold with single or multiple layers of cells of different or identical types.”